Lynn M Schuchter, MD, Chief of the Division of Hematology Oncology at Penn Medicine, has been treating patients with melanoma for three decades. In this presentation, she reviews recent clinical trials to conclude that the developments of the last decade, including the anti-PD-1 agents, the anti-CTLA4 agents and the anti-BRAF and anti-MEK inhibitors have vastly improved the outlook for patients with melanoma, extending the 2-year overall survival from 24% in 2010 to 64% (with nivolumab+ ipilimumab) in 2016.
Related Links
Published
February 7, 2017
Created by
BROADCASTMED